Uzun süreli oral siklofosfamid kullanıma bağlı geçici kalp yetmezliği gelişen bir wegener granülomatozu hastası

Kaynakça (1)

1. Seo P, Stone JH. The antineutrophil cytoplasmic antibody-associated vasculitides. Am J Med 2004; 117: 39-50. [CrossRef] 2. Hoffman GS, Kerr GS, Leavitt RY, Hallahan CW, Lebovics RS, Travis WD, et al. Wegener’s granulomatosis. An analysis of 158 patients. Ann Internal Med 1992; 116: 488-98. 3. de Jonge ME, Huitema ADR, Rodenhuis S, Beijnen JH. Clinical Pharmacokinetics of Cyclophosphamide. Clin Pharmacokinet 2005; 44: 1135-64. [CrossRef] 4. Langford CA. Complications of Cyclophosphamide Therapy Eur Arch Otorhinolaryngol 1997; 254: 65-72. [CrossRef] 5. Mills BA, Roberts RW. Cyclophosphamide-induced cardiomyopathy. A report of two cases and review of the english literature. Cancer 1979; 43: 2223-6. [CrossRef] 6. Goldberg MA, Antin JH, Guinan EC and Rappeport JM. Cyclophosphamide cardiotoxicity: An analysis of dosing as a risk factor. Blood 1986; 68: 1114-8. 7. Gottdiener JS, Appelbaum FR, Ferrans VJ, Deisseroth A, Ziegler J. Cardiotoxicity associated with high-dose cyclophosphamide therapy. Arch Intern Med 1981; 141: 758-63. [CrossRef] 8. Gharib MI, Burnett AK. Chemotherapy-induced cardiotoxicity: Current practice and prospects of prophylaxis. Eur J Heart Fail 2002; 4: 235-42. [CrossRef] 9. Braverman AC, Antin JH, Plappert MT, Cook EF, Lee RT. Cyclophosphamide cardiotoxicity in bone marrow transplantation: a prospective evaluation of new dosing regimens. J Clin Oncol 1991; 9: 1215-23. 10. Buja LM, Ferrans VJ, Graw RG Jr. Cardiac pathologic findings in patients treated with bone marrow transplantation. Hum Pathol 1976; 7: 17-45. [CrossRef] 11. Kupari M, Volin L, Suokas A, Timonen T, Hekali P, Ruutu T. Cardiac involvement in bone marrow transplantation: electrocardiographic changes, arrythmias, heart failure and autopsy findings. Bone Marrow Transplant 1990; 5: 91-8.